Soligenix
Open
$0.43
Prev. Close
$0.43
High
$0.44
Low
$0.43
Market Snapshot
$4.43M
-0.4
-6.14
$119.37K
15
Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. The company is headquartered in Princeton, New Jersey and currently employs 13 full-time employees. The Company’s segments include Specialized Biotherapeutics, and Public Health Solutions. Its Specialized BioTherapeutics business segment is engaged in developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic-resistant and emerging infectious diseases and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2).
Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. The company is headquartered in Princeton, New Jersey and currently employs 13 full-time employees. The Company’s segments include Specialized Biotherapeutics, and Public Health Solutions. Its Specialized BioTherapeutics business segment is engaged in developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic-resistant and emerging infectious diseases and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2).
Recently from Cashu
Soligenix Advances Thermostable Vaccine Development for Bundibugyo Virus Amid Ongoing Outbreak
Soligenix (Ticker: SNGX) is making significant strides in the development of a thermostable vaccine against the Bundibugyo virus, invaluable amidst the ongoing outbreak. Collaborating with Dr. Axel Le…
Soligenix Obtains Orphan Drug Designation for Dusquetide to Treat Behçet's Disease
Soligenix Gains Ground with Orphan Drug Designation for Dusquetide in Behçet's Disease Treatment Soligenix, Inc., a biopharmaceutical company dedicated to addressing unmet needs in rare diseases, achi…
Soligenix's SGX945 Receives PIM Designation, Advancing Treatment for Behçet's Disease
Promising Pathway for Treating Behçet's Disease: Soligenix's SGX945 Receives PIM Designation Soligenix, Inc. announces a significant milestone in its commitment to developing treatments for rare disea…
Soligenix Receives Orphan Drug Designation for Behçet's Disease Treatment Dusquetide in Europe
Soligenix Advances Rare Disease Treatment with Orphan Drug Designation in Europe Soligenix, Inc., a biopharmaceutical company dedicated to developing therapies for rare diseases, secures a significant…